View
4
Download
0
Category
Preview:
Citation preview
Satish K Surabhi. MD.FACC.FSCAI.RPVI
Medical Director, Cardiac Cath LabsAnMed Heart & Vascular Care
None
Evolocumab ( 2976) vs Standard Rx (1489) All CV events 0.95% vs 2.18% MACE 0.95% vs 2.1 % Death 0.14% vs 0.41%
Curves separated early
Cost Access to medicines Compliance Neurocognitive effects 0.9 % vs 0.3% Long term follow up studies
Outcome studies in various populations
Longer acting agents.. Q 6 months? Q 1yr?
Vaccine ?
Combined/ sequential/ intermittent therapy
Recommended